Federal Register Notice: FDA’s Cardiovascular and Renal Drugs Advisory Committee will meet 7/28, from 8 a.m. to 5 p.m. at the Marriott Inn and Conference Center, University of Maryland University College, 3501 University Blvd. East, Adelphi, MD. Contact Elaine Ferguson, c/o Christine Shipe, (301) 796-9001. The committee will discuss AstraZeneca’s NDA for ticagrelor tablets, 90 mg for use in acute coronary syndrome (including heart attacks and any of a group of signs and symptoms, such as chest pain or shortness of breath, that are consistent with blockages in the blood vessels that supply the heart). To view this notice, click here.